Building on earlier work involving the angiogenesis inhibitor thrombospondin-1, or TSP-1, investigators say they've been able to demonstrate in animal studies that a segment of that protein acts to inhibit the growth of ovarian cancer cells. And the use of that therapeutic approach allowed for more effective use of small doses of chemotherapy in treating the deadly disease.
Scientists with the UC Irvine School of Medicine and the Italian Institute of Technology have spotlighted what they call the "very first class" of acid ceramidase inhibitors that could eventually go on to help amp up the effectiveness of chemotherapies.
An investigative team at the University of Cincinnati which specializes in nanotechnology says they've tested a new approach to destroying cancer cells--injecting the specific target cells with iron oxide nanoparticles and then using light-induced heat to burn them up.
The U.K. medical research institute MRC Technology--the tech transfer arm of the government's big Medical Research Council--has struck a deal to collaborate with China's Yabao Pharmaceutical on new Parkinson's drugs for the Asian market. In the deal, Yabao will dedicate part of its research effort to an unidentified kinase target for neurodegeneration.
Blocking the cascade of events that trigger autoimmune disease is a key focus in multiple sclerosis research. And a multidisciplinary team of investigators in Singapore says they have figured out one piece of the puzzle that could offer a new discovery pathway for the disease.
Scientists have been exploring the role of the microbiome--that vast population of bacteria that inhabits the human body, which outnumber cells by 10 to 1--in promoting or debilitating our health. And now researchers say they have identified one family of bacteria, the Christensenellaceae, that appears to play a big role in keeping us lean.
A Scripps effort aimed at better understanding the brain chemistry involved in addiction has uncovered neurons that play a dual role in two key brain systems involved in producing a drug high as well as stress from withdrawal.
A protein known as the ryanodine receptor is responsible for providing a steady supply of calcium needed to keep the human heart pumping efficiently. And a researcher at the University of Cardiff says he's identified a genetic defect that disrupts the heart's normal rhythm and eventually leads to lethal heart failure.
One of the drug cocktails now in preclinical development for Ebola, ZMapp, has been used for a small group of emergency cases. And now two Scripps investigators have come up with a 3-D model to show where its three antibodies stick to the virus, pointing to new and better therapies as well as informing work on other such cocktail therapies.
Working around the notion that cancer-causing mutations on receptors found in bone marrow stem cells could explain why some patients grow resistant to currently used leukemia drugs, researchers at the Indiana University School of Medicine say they've been successful in testing a new approach to fighting the disease.
Brown fat is once again providing clues in how to treat metabolic disorders like diabetes. A group of investigators at the University of Michigan followed up on earlier studies that have examined the role of brown fat in burning calories. Their work led them to NRG4, a hormone secreted by brown fat that may play a role as a messenger with the liver in regulating the conversion of sugar into fat, according to the university.
Investigators at Scripps Translational Science Institute say they have identified the genetic trigger for a rare and potentially lethal form of epilepsy.
After years of lab work and animal studies, investigators at the University of Alabama in Birmingham will use a grant from the JDRF to determine if the blood pressure medicine verapamil can safeguard the pancreatic beta cells needed to produce insulin, pointing to a new approach in treating Type 1 diabetes.
Investigators in Switzerland have discovered a protein found in nature that may serve as a solid target for developers interested in creating stable new antibiotics.
Investigators at Harvard say that they have successfully used CRISPR Cas gene-editing tools to come up with a new approach in curing HIV, a lethal virus that has claimed millions of lives over recent decades. And they're prepping for animal studies now to see if they can provide some preclinical proof-of-concept data to back up their lab experiment.
Investigators at Indiana University School of Medicine have added some fresh preclinical evidence to suggest that the protein Sestrin 3 could one day play a role in treating or preventing Type 2 diabetes.
Roche never publicly described what went wrong with its early-stage BACE drug for Alzheimer's when it killed the program. But a new study from the pharma giant's Genentech unit outlines the potential threat one of their BACE efforts posed to patients--and how they've managed to adjust for it in animal studies that may well open the door to new human trials.
Investigators at Yerkes National Primate Research Center at Emory University may have found new evidence that dispels the theory that macrophages, a type of white blood cell, may harbor HIV for long periods of time, acting as a reservoir.
A new triple-drug combination therapy tested in mice may provide a new treatment avenue for Ewing sarcoma, a rare bone cancer that primarily affects children and adolescents.